Keros Therapeutics Non Currrent Assets Other Over Time

KROS Stock  USD 55.92  2.08  3.86%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Keros Therapeutics Performance and Keros Therapeutics Correlation.
For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.
  
Non Currrent Assets Other is likely to gain to about 2.2 M in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Keros Therapeutics. If investors know Keros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Keros Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.22)
Revenue Per Share
0.019
Quarterly Revenue Growth
47.5
Return On Assets
(0.28)
Return On Equity
(0.44)
The market value of Keros Therapeutics is measured differently than its book value, which is the value of Keros that is recorded on the company's balance sheet. Investors also form their own opinion of Keros Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Keros Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Keros Therapeutics' market value can be influenced by many factors that don't directly affect Keros Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Keros Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Keros Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Keros Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Non Currrent Assets Other Analysis

Compare Keros Therapeutics and related stocks such as Ideaya Biosciences, AnaptysBio, and MeiraGTx Holdings PLC Non Currrent Assets Other Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
IDYA160 K160 K160 K160 K160 K160 K160 K160 K722 K1.3 M82 K397 K205 K782 K416.2 K
ANAB110 K110 K110 K110 K85 K2.3 M3.5 M106 K208 K1.5 M662 K256 K256 K230.4 K218.9 K
MGTX444.8 K444.8 K444.8 K444.8 K444.8 K444.8 K444.8 K123.4 K228.5 K1.3 MM1.2 M1.2 MM3.1 M
JANX(21 K)(21 K)(21 K)(21 K)(21 K)(21 K)(21 K)(21 K)(21 K)(21 K)(155 K)392 K1.4 M3.3 M3.5 M
FENC(1.0)0.00.00.00.00.00.00.00.0262 K27 K27 K211 KK5.7 K
EWTX975 K975 K975 K975 K975 K975 K975 K975 K975 K975 K975 K3.5 M5.3 M348 K330.6 K
HRMYMMMMMMMMM1.7 M902 K4.3 M3.5 M6.6 M3.3 M
AVTE302 K302 K302 K302 K302 K302 K302 K302 K302 K302 K302 K302 K2.6 M2.3 M1.9 M
SNDX755 K755 K755 K2.5 M339 K1.8 M243 K231 K219 K82 K1.2 M983 K9.4 M680 K646 K
MLYS20 K20 K20 K20 K20 K20 K20 K20 K20 K20 K20 KK4.3 M51 K48.5 K
REPL75 K75 K75 K75 K75 K75 K75 K78 K1.2 M1.6 M1.6 M1.6 M1.6 M1.7 M1.3 M
ERAS56 K56 K56 K56 K56 K56 K56 K56 K56 K56 K451 K3.3 M4.8 M4.4 M2.9 M
IPSC206 K206 K206 K206 K206 K206 K206 K206 K206 K206 K1.2 M3.5 M3.2 M2.5 M2.4 M
GLUE1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M5.3 M278 K4.9 M3.2 M
SRZN454 K454 K454 K454 K454 K454 K454 K454 K454 K454 K39 K954 K827 K1.1 M740.1 K
BOLT433 K433 K433 K433 K433 K433 K433 K433 K433 K446 K3.2 M2.6 M2.6 M3.6 M2.4 M
LRMR242 K242 K242 K242 K242 K94 K61 K57 K57 K90 K419 K669 K638 K659 K692 K
KZR75 K75 K75 K75 K75 K75 K75 K356 K282 K282 K282 K282 K674 K5.6 M5.9 M

Keros Therapeutics and related stocks such as Ideaya Biosciences, AnaptysBio, and MeiraGTx Holdings PLC Non Currrent Assets Other description

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

My Equities

My Current Equities and Potential Positions

Keros Therapeutics
KROS
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationMassachusetts; U.S.A
ExchangeNASDAQ Exchange
USD 55.92

Additional Tools for Keros Stock Analysis

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.